Thursday, March 07, 2019 11:23:59 AM
This time, with a design freeze, is a much clearer message to the market that there not only will not be a delay, but also likely even better pre-clinical results with improvements.
The first pre-clinical studies will immediately follow design freeze. So it stands to reason that we will climb into that range 10-15 fairly quickly (by the fall) following an initial bump in PPS with design freeze (early summer). My guess is 6-8 early summer.
We'd want that to happen, to have the 40 million in warrants for Q3 and Q4, and a bit beyond. Otherwise, yet another financing (but it is becoming less and less relevant). Things are pretty bright at this point as is.
End of year, anything is possible with successful human trials and FDA submission as far as PPS. That will give us some wild press...tummies with no scars....road shows as we wait for FDA approval...and some real initial serious interest from acquirers..
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM